明德生物(002932.SZ)发布前三季度业绩，归母净利润1351.55万元，下降83.30%

Core Viewpoint - Mindray Bio (002932.SZ) reported a slight increase in revenue for the first three quarters of 2025, but a significant decline in net profit, indicating potential challenges in profitability despite stable revenue growth [1] Financial Performance - The company's revenue for the first three quarters reached 227 million yuan, reflecting a year-on-year growth of 0.53% [1] - The net profit attributable to shareholders was 13.52 million yuan, showing a substantial decrease of 83.30% compared to the previous year [1] - The net loss attributable to shareholders after deducting non-recurring gains and losses amounted to 63.33 million yuan [1] - Basic earnings per share were reported at 0.0616 yuan [1]